Puma Biotechnology, Inc. (PBYI)
USD 2.88
(-1.54%)
USD 2.88
(-1.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 26.9 Million USD | -29.35% |
| 2022 | 38.08 Million USD | -28.88% |
| 2021 | 53.54 Million USD | 50.17% |
| 2020 | 35.65 Million USD | -40.8% |
| 2019 | 60.22 Million USD | 38.5% |
| 2018 | 43.48 Million USD | 230.89% |
| 2017 | -33.22 Million USD | 82.92% |
| 2016 | -194.5 Million USD | -515.51% |
| 2015 | -31.6 Million USD | 17.92% |
| 2014 | -38.5 Million USD | 10.56% |
| 2013 | -43.04 Million USD | 68.67% |
| 2012 | -137.4 Million USD | -157.39% |
| 2011 | -53.38 Million USD | -11554387.88% |
| 2010 | -462.00 USD | 80.81% |
| 2009 | -2408.00 USD | -3198.63% |
| 2008 | -73.00 USD | 99.99% |
| 2007 | -1.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 31.43 Million USD | -7.49% |
| 2024 Q1 | 33.98 Million USD | 26.31% |
| 2023 FY | 26.9 Million USD | -29.35% |
| 2023 Q2 | 52.93 Million USD | 1.32% |
| 2023 Q3 | 30.42 Million USD | -42.52% |
| 2023 Q4 | 26.9 Million USD | -11.56% |
| 2023 Q1 | 52.24 Million USD | 37.18% |
| 2022 Q3 | 36.94 Million USD | -41.12% |
| 2022 FY | 38.08 Million USD | -28.88% |
| 2022 Q1 | 52.17 Million USD | -2.55% |
| 2022 Q2 | 62.74 Million USD | 20.26% |
| 2022 Q4 | 38.08 Million USD | 3.07% |
| 2021 Q4 | 53.54 Million USD | 0.6% |
| 2021 FY | 53.54 Million USD | 50.17% |
| 2021 Q1 | 25.48 Million USD | -28.54% |
| 2021 Q2 | 31.44 Million USD | 23.41% |
| 2021 Q3 | 53.22 Million USD | 69.24% |
| 2020 Q4 | 35.65 Million USD | 16.2% |
| 2020 FY | 35.65 Million USD | -40.8% |
| 2020 Q1 | 37.03 Million USD | -38.51% |
| 2020 Q2 | 29.68 Million USD | -19.84% |
| 2020 Q3 | 30.68 Million USD | 3.35% |
| 2019 Q4 | 60.22 Million USD | -1.49% |
| 2019 FY | 60.22 Million USD | 38.5% |
| 2019 Q1 | 130.92 Million USD | 201.07% |
| 2019 Q2 | 92.6 Million USD | -29.27% |
| 2019 Q3 | 61.13 Million USD | -33.98% |
| 2018 FY | 43.48 Million USD | 230.89% |
| 2018 Q3 | 52.75 Million USD | 116.59% |
| 2018 Q2 | 24.35 Million USD | 181.2% |
| 2018 Q1 | -29.99 Million USD | 9.71% |
| 2018 Q4 | 43.48 Million USD | -17.57% |
| 2017 FY | -33.22 Million USD | 82.92% |
| 2017 Q4 | -33.22 Million USD | 58.32% |
| 2017 Q3 | -79.71 Million USD | 1.36% |
| 2017 Q2 | -80.81 Million USD | 23.09% |
| 2017 Q1 | -105.08 Million USD | 45.97% |
| 2016 Q4 | -194.5 Million USD | -270.19% |
| 2016 Q3 | -52.54 Million USD | 9.16% |
| 2016 FY | -194.5 Million USD | -515.51% |
| 2016 Q2 | -57.83 Million USD | 26.06% |
| 2016 Q1 | -78.21 Million USD | -147.53% |
| 2015 Q2 | -59.83 Million USD | 61.51% |
| 2015 Q1 | -155.46 Million USD | -303.81% |
| 2015 Q4 | -31.6 Million USD | -33.91% |
| 2015 FY | -31.6 Million USD | 17.92% |
| 2015 Q3 | -23.59 Million USD | 60.56% |
| 2014 FY | -38.5 Million USD | 10.56% |
| 2014 Q1 | -163.38 Million USD | -279.57% |
| 2014 Q3 | -28.26 Million USD | 48.94% |
| 2014 Q2 | -55.35 Million USD | 66.12% |
| 2014 Q4 | -38.5 Million USD | -36.22% |
| 2013 Q2 | -60.9 Million USD | 33.51% |
| 2013 Q4 | -43.04 Million USD | 16.03% |
| 2013 Q3 | -51.26 Million USD | 15.83% |
| 2013 Q1 | -91.6 Million USD | 33.33% |
| 2013 FY | -43.04 Million USD | 68.67% |
| 2012 Q4 | -137.4 Million USD | -312.04% |
| 2012 Q2 | -41 Million USD | 18.28% |
| 2012 FY | -137.4 Million USD | -157.39% |
| 2012 Q1 | -50.17 Million USD | 6.01% |
| 2012 Q3 | -33.34 Million USD | 18.67% |
| 2011 Q2 | -1747.00 USD | -824.34% |
| 2011 Q4 | -53.38 Million USD | -30685.47% |
| 2011 Q3 | 174.53 Thousand USD | 10090.44% |
| 2011 FY | -53.38 Million USD | -11554387.88% |
| 2011 Q1 | -189.00 USD | 59.09% |
| 2010 Q4 | -462.00 USD | 78.0% |
| 2010 FY | -462.00 USD | 80.81% |
| 2010 Q3 | -2100.00 USD | -16.47% |
| 2010 Q2 | -1803.00 USD | -4297.56% |
| 2010 Q1 | -41.00 USD | 98.3% |
| 2009 Q2 | -2437.00 USD | -3537.31% |
| 2009 Q1 | -67.00 USD | 8.22% |
| 2009 FY | -2408.00 USD | -3198.63% |
| 2009 Q4 | -2408.00 USD | -4716.0% |
| 2009 Q3 | -50.00 USD | 97.95% |
| 2008 Q1 | -2.16 Million USD | -53.94% |
| 2008 Q3 | -72 Thousand USD | 96.86% |
| 2008 Q4 | -73.00 USD | 99.9% |
| 2008 FY | -73.00 USD | 99.99% |
| 2008 Q2 | -2.29 Million USD | -5.77% |
| 2007 FY | -1.4 Million USD | 0.0% |
| 2007 Q3 | -8.61 Million USD | 0.0% |
| 2007 Q4 | -1.4 Million USD | 83.67% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 148.096% |
| Alkermes plc | -166.73 Million USD | 116.136% |
| Agenus Inc. | 274.13 Million USD | 90.186% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 98.561% |
| Aptorum Group Limited | 1.35 Million USD | -1882.615% |
| Ardelyx, Inc. | 34.51 Million USD | 22.042% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -528.621% |
| Bicycle Therapeutics plc | -481.46 Million USD | 105.588% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 25.601% |
| ChromaDex Corporation | -24.04 Million USD | 211.88% |
| Chimerix, Inc. | -25.51 Million USD | 205.44% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -286.118% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 213.633% |
| CRISPR Therapeutics AG | -150.84 Million USD | 117.836% |
| Precision BioSciences, Inc. | -85.41 Million USD | 131.501% |
| Dyadic International, Inc. | -6.37 Million USD | 521.834% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 268.863% |
| Fortress Biotech, Inc. | 7.66 Million USD | -251.011% |
| Lantern Pharma Inc. | -21.7 Million USD | 223.967% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 124.34% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 414.93% |
| Incyte Corporation | -3.17 Billion USD | 100.847% |
| IO Biotech, Inc. | -140.69 Million USD | 119.122% |
| Jaguar Health, Inc. | 29.39 Million USD | 8.458% |
| Novavax, Inc. | -298.29 Million USD | 109.02% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -404.122% |
| Opthea Limited | 28.15 Million USD | 4.448% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 260.254% |
| ContextLogic Inc. | -232 Million USD | 111.597% |
| MiMedx Group, Inc. | -33.9 Million USD | 179.363% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -163.904% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 1261.186% |
| NextCure, Inc. | -6.47 Million USD | 515.393% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 153.276% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 521.775% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -121.199% |
| Vaxcyte, Inc. | -368.22 Million USD | 107.307% |
| PDS Biotechnology Corporation | -32.7 Million USD | 182.256% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -55.718% |
| Pharming Group N.V. | 109.8 Million USD | 75.497% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 254.662% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 115.354% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 245.277% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 245.277% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 478.944% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 559.13% |
| Acelyrin, Inc. | -216.9 Million USD | 112.404% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 579.567% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 1660.615% |
| Summit Therapeutics Inc. | 34.67 Million USD | 22.406% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 495.487% |
| Senti Biosciences, Inc. | 1.74 Million USD | -1446.264% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 114.574% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 134.738% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 543.83% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -26867.294% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -4184.236% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 122.987% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 115.993% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 75.733% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 454.2% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 120.838% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -290.233% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 111.101% |
| Immix Biopharma, Inc. | -17.5 Million USD | 253.657% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 108.495% |
| MEI Pharma, Inc. | -3.7 Million USD | 826.181% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -115.051% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 83.365% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 3.195% |
| Fortress Biotech, Inc. | 7.66 Million USD | -251.011% |
| Precigen, Inc. | -481 Thousand USD | 5693.555% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -91.073% |
| AlloVir, Inc. | -62.69 Million USD | 142.916% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 148.378% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 56.37% |
| ImmuCell Corporation | 10.99 Million USD | -144.801% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 117.454% |
| Onconetix, Inc. | 5.33 Million USD | -404.648% |
| PureTech Health plc | -167.19 Million USD | 116.092% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 188.329% |
| Elevation Oncology, Inc. | -19.11 Million USD | 240.731% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 648.075% |
| Seer, Inc. | -4.24 Million USD | 734.552% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 211.932% |
| Innoviva, Inc. | 255.56 Million USD | 89.472% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 148.162% |
| ESSA Pharma Inc. | -33.62 Million USD | 180.023% |
| GlycoMimetics, Inc. | -40.98 Million USD | 165.647% |
| GT Biopharma, Inc. | -1.02 Million USD | 2735.162% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 139.693% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 56.078% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 120.067% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 294.176% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 193.187% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 35814.286% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 187.178% |
| Aptose Biosciences Inc. | -8.19 Million USD | 428.316% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 959.854% |
| Soligenix, Inc. | -4.95 Million USD | 643.36% |
| Century Therapeutics, Inc. | 847 Thousand USD | -3076.505% |
| Kura Oncology, Inc. | -20.11 Million USD | 233.736% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 165.741% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 420.374% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -1376.921% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 941.57% |
| Autolus Therapeutics plc | -186.59 Million USD | 114.419% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 154.57% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 109.755% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 21.487% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 83.631% |
| GRI Bio, Inc. | -1.79 Million USD | 1599.721% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 399.509% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 180.9% |
| IGM Biosciences, Inc. | -72.6 Million USD | 137.056% |
| INmune Bio, Inc. | -25.41 Million USD | 205.879% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 82.176% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 153.11% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 265.576% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 1032.606% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 29.225% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 165.327% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 15.619% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 92.881% |
| Verastem, Inc. | -37.27 Million USD | 172.174% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 396.539% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 151.878% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 277.767% |
| Histogen Inc. | -7.48 Million USD | 459.356% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 224.521% |
| Surrozen, Inc. | -32.66 Million USD | 182.369% |
| Organovo Holdings, Inc. | -1.5 Million USD | 1885.335% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 740.064% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -41.902% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -928.479% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -547.377% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 421.018% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 161.933% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 284.573% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 108.493% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 3826.145% |
| Apollomics, Inc. | -27.39 Million USD | 198.211% |
| Amarin Corporation plc | -191.04 Million USD | 114.083% |
| Mesoblast Limited | 55.96 Million USD | 51.924% |
| Turnstone Biologics Corp. | -14.58 Million USD | 284.483% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 206.378% |
| Synaptogenix, Inc. | -28.66 Million USD | 193.872% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 2974.466% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 44.79% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 3220.907% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 470.282% |
| Exelixis, Inc. | -73.05 Million USD | 136.831% |
| Better Therapeutics, Inc. | -860 Thousand USD | 3228.488% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 212.043% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 111.147% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -3555.243% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 461.717% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -2045.534% |
| Gritstone bio, Inc. | 39.49 Million USD | 31.869% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 131.991% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 1122.172% |
| Avid Bioservices, Inc. | 169.72 Million USD | 84.148% |
| Insmed Incorporated | 721.62 Million USD | 96.272% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 394.317% |
| MediWound Ltd. | -5.32 Million USD | 605.543% |
| OmniAb, Inc. | 9.2 Million USD | -192.35% |
| Alector, Inc. | -35.63 Million USD | 175.497% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 68.705% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 645.962% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -103.225% |
| Zai Lab Limited | -775 Million USD | 103.472% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 92.1% |
| Aura Biosciences, Inc. | -21.52 Million USD | 224.994% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 132.62% |
| Immunic, Inc. | -45.34 Million USD | 159.341% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 113.925% |
| Veracyte, Inc. | -203.82 Million USD | 113.2% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 95.785% |
| FibroGen, Inc. | 56.76 Million USD | 52.605% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -202.134% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 1051.688% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 1399.54% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.414% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 905.298% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 116.211% |
| TG Therapeutics, Inc. | 17.86 Million USD | -50.627% |
| Galecto, Inc. | -21.21 Million USD | 226.815% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 213.118% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 98.286% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 209.942% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 333.814% |
| XBiotech Inc. | -200.02 Million USD | 113.451% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 131.991% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -494.192% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 176.298% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 134.843% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -372.764% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 115.788% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 129.126% |
| Vaxxinity, Inc. | 10.13 Million USD | -165.545% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 96.346% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 349.871% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 140.792% |
| NexImmune, Inc. | -3.13 Million USD | 958.585% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 879.251% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 278.044% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 199.28% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 399.742% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 21697.431% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 166.314% |
| Ainos, Inc. | 4.07 Million USD | -559.771% |
| Pluri Inc. | 22.82 Million USD | -17.854% |
| Prothena Corporation plc | -608.34 Million USD | 104.423% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 122.656% |
| Celularity Inc. | 65.19 Million USD | 58.728% |
| Rallybio Corporation | -24.1 Million USD | 211.63% |
| Cue Biopharma, Inc. | -33.81 Million USD | 179.556% |
| MeiraGTx Holdings plc | -40.3 Million USD | 166.758% |
| Omeros Corporation | 331.17 Million USD | 91.876% |
| Humacyte, Inc. | -22.48 Million USD | 219.652% |
| Immunocore Holdings plc | -358.59 Million USD | 107.503% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 209.481% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 187.068% |
| Blueprint Medicines Corporation | 702.83 Million USD | 96.172% |
| CalciMedica, Inc. | -5.53 Million USD | 586.528% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 114.294% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 363.413% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 167.2% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 180.91% |
| Pulmatrix, Inc. | -10.41 Million USD | 358.28% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 550.142% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 170.539% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 124.151% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 144.884% |
| Cytokinetics, Incorporated | 642.37 Million USD | 95.812% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 562.047% |
| Nutriband Inc. | -251.65 Thousand USD | 10791.139% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 178.856% |
| Vor Biopharma Inc. | 4.3 Million USD | -525.698% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.446% |
| Evogene Ltd. | -19.63 Million USD | 237.033% |
| ProKidney Corp. | -56.23 Million USD | 147.843% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 155.278% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 391.268% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 98.027% |
| CorMedix Inc. | -43.05 Million USD | 162.493% |
| BioLineRx Ltd. | 7.33 Million USD | -266.753% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 197.961% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 41.697% |
| Atai Life Sciences N.V. | -28.55 Million USD | 194.212% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -1106.216% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 217.922% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -51.706% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 135.838% |
| MediciNova, Inc. | -50.78 Million USD | 152.98% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 134.141% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 119704.357% |
| GeoVax Labs, Inc. | -6.45 Million USD | 516.964% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 113.465% |
| Biomea Fusion, Inc. | -166.57 Million USD | 116.152% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 115.033% |
| Mereo BioPharma Group plc | -51.46 Million USD | 152.274% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 128.368% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 109.159% |
| Absci Corporation | -72.59 Million USD | 137.06% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -489.247% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 111.476% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 128.558% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 128.115% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 168.858% |
| Allakos Inc. | -24.97 Million USD | 207.728% |
| Imunon, Inc. | -4.21 Million USD | 738.489% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 282.506% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 119.871% |
| BioAtla, Inc. | -109.01 Million USD | 124.681% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -3555.243% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 2965.282% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -124.845% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 226.892% |
| XOMA Corporation | -29 Million USD | 192.776% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 262.47% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 398.414% |
| aTyr Pharma, Inc. | -7.44 Million USD | 461.189% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 121.587% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 112.925% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 132.9% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 129.004% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 3231.46% |
| Akari Therapeutics, Plc | -3.84 Million USD | 799.74% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1557.845% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.052% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 2364.473% |
| UroGen Pharma Ltd. | 4.39 Million USD | -512.731% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 76.291% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -37287.788% |
| Orgenesis Inc. | 21.78 Million USD | -23.508% |
| Entera Bio Ltd. | -10.62 Million USD | 353.128% |
| GH Research PLC | -78.07 Million USD | 134.46% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 220.715% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 200.923% |
| Xencor, Inc. | 29.64 Million USD | 9.24% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 1465.866% |
| Replimune Group, Inc. | 1.41 Million USD | -1805.453% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 11085.758% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 121.283% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 2364.473% |
| Portage Biotech Inc. | -4.98 Million USD | 640.153% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 119704.357% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 140.69% |
| OncoCyte Corporation | -6.56 Million USD | 509.95% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -2898.062% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 690.586% |
| Purple Biotech Ltd. | -14.13 Million USD | 290.303% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 213.256% |
| scPharmaceuticals Inc. | -6.54 Million USD | 511.077% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 261.183% |
| HilleVax, Inc. | -165.48 Million USD | 116.258% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 1160.087% |
| Tharimmune, Inc. | -10.93 Million USD | 346.037% |
| Genprex, Inc. | -6.73 Million USD | 499.324% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 107.295% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 130.415% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 2020.414% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 911.138% |
| OKYO Pharma Limited | -826.84 Thousand USD | 3353.923% |
| Savara Inc. | 153 Thousand USD | -17484.967% |
| Curis, Inc. | -23.88 Million USD | 212.634% |
| Daré Bioscience, Inc. | -5.15 Million USD | 621.626% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 3567.086% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 533.392% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -2170.464% |
| BeiGene, Ltd. | -2.25 Billion USD | 101.194% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -118.057% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 104.424% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 114.497% |
| Erasca, Inc. | -37.21 Million USD | 172.294% |
| bluebird bio, Inc. | 108.57 Million USD | 75.219% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2189.071% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 92.896% |
| DBV Technologies S.A. | -126.98 Million USD | 121.187% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2189.071% |
| Moderna, Inc. | -2.9 Billion USD | 100.926% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 359.901% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 347.562% |
| Molecular Templates, Inc. | 707 Thousand USD | -3705.516% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 185.764% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 92.238% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 132.786% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 129.331% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 183.369% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 178.267% |
| MacroGenics, Inc. | -66.98 Million USD | 140.166% |
| RenovoRx, Inc. | -1.17 Million USD | 2393.691% |
| Adicet Bio, Inc. | -138.78 Million USD | 119.386% |
| Prime Medicine, Inc. | -27.94 Million USD | 196.292% |
| Aditxt, Inc. | 18.12 Million USD | -48.475% |
| Adagene Inc. | -87.62 Million USD | 130.704% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 745.912% |
| Quantum-Si incorporated | -118.55 Million USD | 122.694% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 25.274% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 459.972% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 155.464% |
| SciSparc Ltd. | -2.06 Million USD | 1402.906% |
| Vericel Corporation | 1.27 Million USD | -2006.891% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 324.363% |
| Minerva Neurosciences, Inc. | 41 Million USD | 34.385% |
| Generation Bio Co. | 31.44 Million USD | 14.446% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 115.342% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 187.006% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 76.924% |
| Invivyd, Inc. | -198.47 Million USD | 113.556% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 129.805% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 1222.123% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 138.007% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 494.212% |
| 2seventy bio, Inc. | 181.71 Million USD | 85.194% |
| ADMA Biologics, Inc. | 90.06 Million USD | 70.127% |
| Clene Inc. | 3.34 Million USD | -705.539% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 396.222% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 225.076% |
| GeoVax Labs, Inc. | -6.45 Million USD | 516.964% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 107.818% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 203.482% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 84.856% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 757.572% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -437.885% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 616.51% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 120.648% |
| Evaxion Biotech A/S | 5.28 Million USD | -408.905% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 123.901% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 120.495% |
| Trevena, Inc. | 2.25 Million USD | -1091.541% |
| Surrozen, Inc. | -32.66 Million USD | 182.369% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 152.233% |
| Cingulate Inc. | 3.08 Million USD | -772.779% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 1016.071% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -274.356% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 389.574% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 133.918% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 120.468% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 125.492% |
| Clearmind Medicine Inc. | -3.94 Million USD | 782.411% |
| Kronos Bio, Inc. | -36.05 Million USD | 174.624% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -185.95% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1745.175% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 149.589% |
| Statera Biopharma, Inc. | 14.41 Million USD | -86.628% |
| ImmunityBio, Inc. | 618.22 Million USD | 95.648% |
| Korro Bio, Inc. | -132.94 Million USD | 120.238% |
| Kineta, Inc. | -4.54 Million USD | 692.491% |
| BioVie Inc. | -17.73 Million USD | 251.728% |
| Codexis, Inc. | -43.27 Million USD | 162.178% |
| Celularity Inc. | 65.19 Million USD | 58.728% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 949.006% |
| Celcuity Inc. | 6.78 Million USD | -296.624% |
| Virax Biolabs Group Limited | -3.36 Million USD | 899.568% |
| Cibus, Inc. | -8.07 Million USD | 433.065% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 736.202% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -488.731% |
| IN8bio, Inc. | -16.38 Million USD | 264.165% |
| Kodiak Sciences Inc. | -103.87 Million USD | 125.901% |
| Annexon, Inc. | -193.75 Million USD | 113.886% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -74636.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 253.752% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 865.87% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 97.448% |
| Eyenovia, Inc. | 1.25 Million USD | -2037.519% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 929.633% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 180.925% |
| Arcellx, Inc. | -296.95 Million USD | 109.06% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 237.932% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 145.699% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 229.807% |
| Moolec Science SA | 117.61 Thousand USD | -22775.289% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 170.067% |
| Geron Corporation | 14.76 Million USD | -82.271% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 170.956% |
| Royalty Pharma plc | 5.65 Billion USD | 99.525% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 119.025% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 484.939% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 601.691% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 119.118% |
| Humacyte, Inc. | -22.48 Million USD | 219.652% |
| Structure Therapeutics Inc. | -124.33 Million USD | 121.638% |
| 89bio, Inc. | -289.05 Million USD | 109.308% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 206.588% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 1608.974% |
| Genelux Corporation | -6.89 Million USD | 489.984% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 186.625% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 67.817% |
| Notable Labs, Ltd. | -9.77 Million USD | 375.215% |
| Liquidia Corporation | -80.17 Million USD | 133.557% |
| Mustang Bio, Inc. | -3.73 Million USD | 820.155% |
| Immunovant, Inc. | -635.22 Million USD | 104.235% |
| Quantum-Si incorporated | -118.55 Million USD | 122.694% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 253.183% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 749.409% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -235.181% |
| Acasti Pharma Inc. | -23 Million USD | 216.953% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 899.025% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 265.576% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 119.533% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 963.346% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 221.019% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 244.892% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 115.894% |
| PepGen Inc. | -60.67 Million USD | 144.346% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 217.1% |
| United Therapeutics Corporation | -507.7 Million USD | 105.299% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 240.672% |
| Solid Biosciences Inc. | -47.75 Million USD | 156.346% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 3220.907% |
| Immuneering Corporation | -54.94 Million USD | 148.969% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 740.064% |
| Silo Pharma, Inc. | -3.52 Million USD | 863.412% |
| Belite Bio, Inc | -87.27 Million USD | 130.829% |
| XOMA Corporation | -29 Million USD | 192.776% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 138.057% |
| Bionomics Limited | 227 Million USD | 88.148% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 123.138% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1162.179% |
| uniQure N.V. | -102.95 Million USD | 126.134% |
| Cassava Sciences, Inc. | -121.13 Million USD | 122.211% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 745.912% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 34.3% |
| Forte Biosciences, Inc. | -11.96 Million USD | 324.939% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 969.53% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -25282.075% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 929.633% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -202.134% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 462.797% |
| Altimmune, Inc. | -134.48 Million USD | 120.006% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 86.416% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1162.179% |
| Compugen Ltd. | -12.9 Million USD | 308.501% |
| Peak Bio, Inc. | 10.34 Million USD | -160.199% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 9607.067% |
| Benitec Biopharma Inc. | -50.58 Million USD | 153.191% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 125.786% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -36.956% |
| Zura Bio Limited | -99.8 Million USD | 126.957% |
| PolyPid Ltd. | 6.17 Million USD | -336.062% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 63.701% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -36.956% |
| Instil Bio, Inc. | 75.35 Million USD | 64.297% |
| argenx SE | -2.02 Billion USD | 101.326% |
| Immunome, Inc. | -97.02 Million USD | 127.729% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 219.604% |
| Verona Pharma plc | -220.44 Million USD | 112.205% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 137.502% |
| Shattuck Labs, Inc. | -121.42 Million USD | 122.158% |
| CervoMed Inc. | -7.79 Million USD | 445.253% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 114.504% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 715.253% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 120.423% |
| Moolec Science SA | 117.61 Thousand USD | -22775.289% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 1275.93% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -69.231% |
| AnaptysBio, Inc. | -18.15 Million USD | 248.229% |
| Design Therapeutics, Inc. | -18.15 Million USD | 248.237% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 138.228% |
| NeurAxis, Inc. | 145.7 Thousand USD | -18366.026% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -139.539% |
| Lumos Pharma, Inc. | -28.49 Million USD | 194.427% |
| Achilles Therapeutics plc | -126.92 Million USD | 121.198% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 137.502% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 4203.061% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 229.514% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1745.175% |
| Nutriband Inc. | -251.65 Thousand USD | 10791.139% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 304.275% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 461.626% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 92.091% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -13.356% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 106.013% |
| Palisade Bio, Inc. | -12.06 Million USD | 323.037% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 119.175% |
| Beam Therapeutics Inc. | -262.72 Million USD | 110.241% |
| Neurogene Inc. | -131.95 Million USD | 120.39% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -23.327% |
| AEON Biopharma, Inc. | -4.88 Million USD | 651.332% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 107.133% |
| Sesen Bio, Inc. | -112.55 Million USD | 123.904% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 126.943% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 1245.97% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 168.941% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 132.306% |
| Athira Pharma, Inc. | -88.99 Million USD | 130.231% |
| Vaccinex, Inc. | -1.28 Million USD | 2188.898% |
| HCW Biologics Inc. | 2.85 Million USD | -841.829% |
| XOMA Corporation | -29 Million USD | 192.776% |
| Nektar Therapeutics | 210.24 Million USD | 87.203% |
| Arvinas, Inc. | -313.8 Million USD | 108.574% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1557.845% |
| Merus N.V. | -192.88 Million USD | 113.949% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 55.147% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 487.792% |
| Rezolute, Inc. | -68.16 Million USD | 139.469% |
| Clene Inc. | 3.34 Million USD | -705.539% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 304.027% |
| BeyondSpring Inc. | -13.75 Million USD | 295.602% |
| Synlogic, Inc. | -6.68 Million USD | 502.468% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -2272.575% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 418.214% |
| Peak Bio, Inc. | 10.34 Million USD | -160.199% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 132.644% |
| Krystal Biotech, Inc. | -350.23 Million USD | 107.682% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 78.324% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 115.92% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 952.194% |
| MannKind Corporation | 143.89 Million USD | 81.303% |
| Ikena Oncology, Inc. | -109.15 Million USD | 124.648% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 455.369% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 181.284% |
| Gossamer Bio, Inc. | 180.35 Million USD | 85.082% |
| CohBar, Inc. | -5.93 Million USD | 553.654% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 190.443% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -489.247% |
| Legend Biotech Corporation | -949.39 Million USD | 102.834% |
| Mural Oncology plc | -255.84 Million USD | 110.516% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 16.483% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 671.154% |
| Disc Medicine, Inc. | -358.28 Million USD | 107.509% |
| Champions Oncology, Inc. | 4.81 Million USD | -459.123% |
| REGENXBIO Inc. | 54.76 Million USD | 50.875% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 10105.318% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 117.815% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 398.546% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 133.347% |
| Vaxart, Inc. | -8.24 Million USD | 426.477% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 153.617% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 121.157% |
| Cellectis S.A. | -43.85 Million USD | 161.35% |
| Longeveron Inc. | -2.9 Million USD | 1025.206% |
| Repare Therapeutics Inc. | -107.85 Million USD | 124.945% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 97.222% |
| Inozyme Pharma, Inc. | 12 Million USD | -124.134% |
| Revolution Medicines, Inc. | -608.2 Million USD | 104.424% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 2287.398% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 110.148% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 117.928% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 271.95% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 3735.811% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.281% |
| Denali Therapeutics Inc. | -74.86 Million USD | 135.938% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 324.363% |
| Veru Inc. | 4.77 Million USD | -462.87% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 339.241% |
| Cingulate Inc. | 3.08 Million USD | -772.779% |
| Passage Bio, Inc. | 4.58 Million USD | -486.805% |
| Context Therapeutics Inc. | -14.44 Million USD | 286.196% |
| Exicure, Inc. | 5.84 Million USD | -359.993% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 111.679% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 167.993% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -71.468% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 145.74% |
| Nuvalent, Inc. | -335.38 Million USD | 108.022% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -1451.31% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 136.123% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 402.643% |
| OmniAb, Inc. | 9.2 Million USD | -192.35% |
| Anew Medical, Inc. | 1.43 Million USD | -1778.231% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -64.238% |
| Lipocine Inc. | -4.75 Million USD | 665.874% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 124.497% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -76.646% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 153.11% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -8.087% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 500.312% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 140.872% |
| Ocugen, Inc. | -32.52 Million USD | 182.731% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 131.44% |
| Q32 Bio Inc. | -37.94 Million USD | 170.9% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 4384.236% |
| Alumis Inc. Common Stock | -13.52 Million USD | 298.869% |
| Equillium, Inc. | -22.39 Million USD | 220.155% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 205.229% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 182.463% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 10952.51% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 79.928% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -741.307% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -8091.73% |
| Dominari Holdings Inc. | 195 Thousand USD | -13697.436% |
| Edesa Biotech, Inc. | -5.26 Million USD | 610.831% |
| vTv Therapeutics Inc. | -8.91 Million USD | 401.727% |
| Bio-Techne Corporation | 267.74 Million USD | 89.951% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 265.988% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 122.783% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 420.183% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 312.671% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 110.976% |
| Nkarta, Inc. | 57.29 Million USD | 53.045% |
| BioCardia, Inc. | 212 Thousand USD | -12591.038% |
| Iterum Therapeutics plc | 13.43 Million USD | -100.216% |